CTMX | Cytomx therapeutics inc - Stock Value & PE Ratio Analysis

3

24

15

Average Growth

AI analysis rates CTMX with a medium value score of 3.
It is mainly due to stable revenue growth, but with concerns regarding unstable operating cash flow.
Over the past 3 months, CTMX has maintained a consecutive value rating of 3.0, close to the rating of 3.4 over the past 3 years, indicating stable enterprise value.
Compared to all stocks in the Health Care sector, CTMX has a medium value rating.

CTMX Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/03/09 (Weekly Update)

CTMX Financial Forecast

Unit : USD

Update to 2025/5/17 (Quarterly Update)

CTMX Earnings Table

Unit : USD

QTR	Non-GAAP EPS	EPS YoY	EPS Surprise %	Sales	Sales YoY	Sales Surprise %	NPM
Current	0.22	450%	-210%	38.09M	44.4%	192.1%	17.2%
2024Q2	0.07	450%	-141.2%	33.43M	35.2%	147%	-26%
2024Q1	-0.08	-60%	14.3%	25.12M	6.9%	25.6%	33.3%
2023Q3	0.01	102.4%	134.7%	41.46M	4,283%	93.5%	11.3%
2023Q2	0.04	111.4%	-121.1%	26.38M	56%	29.3%	-4.4%

Update to 2025/5/17 (Quarterly Update)

CTMX Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

CTMX Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry

Exit

The Backtest Result of CTMX from 2015/10 till Now

18.71%
Cumulative Return: 1.81%
Annual Return: 89.63%
Volatility: 0.02
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from October, 2015 to May, 2025. (Total Trades: 1)